This also serves as a good reminder of how long-term an investment this is from an investor’s perspective, when the 5-7 year timeframe for bringing a drug to market in an optimal situation is mentioned 
2 Likes
According to the June owner update, Nanoform is again the only seller in the top 20, -101k shares. At this rate, Nanoform will have enough shares to sell for another 3-5 months.
10 Likes
Kakkonen trusts this, in addition to Endomines, Incap, Componenta, and Nextim.
8 Likes
On Kauppalehti’s side: As for Herantis Pharma, Kakkonen’s focus is on the turn of August-September. At that time, the results of the phase 1b clinical trial of the drug developed by the company for the treatment of Parkinson’s disease will be obtained.
11 Likes
Anavex released a new update today on Blarcamesine’s Alzheimer’s disease trials: https://www.anavex.com/post/anavex-life-sciences-announces-positive-precision-medicine-results-from-up-to-4-years-of-oral-blarca.
- New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start
- ADAS-Cog13 difference: −5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P >< 0.0001)
- Restoring impaired autophagy as early event, preceding amyloid-beta and tau
“In Alzheimer’s disease clinical trials, ‘time saved’ refers to the estimated amount of time a treatment delays the progression of the disease, allowing patients to maintain functionality and independence longer.”
Blarcamesine and HER-096 thus have the same target pathway, autophagy, which the molecules affect.
7 Likes
Good update, and for many familiar with medicine, it probably opens up easily, but how could that be summarized for someone who doesn’t understand that language at all? And if Anavex has received some promising research results, does that mean positive results are also expected for Herantis?
4 Likes
The first thing to note is that Anavex’s most advanced trials have been conducted for the treatment of Alzheimer’s disease, and Herantis’s trials are currently focused on the treatment of Parkinson’s disease. That preliminary promising result of Blarcamesine in the treatment of Alzheimer’s disease could indicate that the same signaling pathway, which both of these drugs target, could work for different types of neurodegenerative diseases. Thus, HER-096 could also work for the treatment of Alzheimer’s disease.
Another positive aspect of these Anavex results is that they confirm the targeting of this signaling pathway as a viable candidate for the treatment of neurodegenerative diseases. Currently, there are no good disease-modifying drugs for these diseases (excluding anti-amyloid antibodies for Alzheimer’s, but anti-synuclein antibodies have not, to my knowledge, worked as desired for Parkinson’s so far). If an effective molecule is found for this pathway that provides the desired protection for nerve cells, then other competing molecules that target the same pathway may suddenly start to look much more interesting to large pharma companies wanting to enter the same market.
18 Likes
H1 report on August 21, 2025, and a link to the webinar at 10:00 AM.
Shareholders, investors, analysts, and media are invited to register and participate in the event via the following link: Herantis H1 2025 Report
A recording of the webinar will be available for listening and viewing after the live event at: Herantis Pharma - Public materials.
7 Likes
Herantis antaa väliaikatietoa. Koko tiedote Herantiksen kotisivuilla.
Herantis Pharma Plc | Press release | 14 August 2025, at 15:30 EEST
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
- Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week period
- Primary objective is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers, and aims to identify novel treatment response biomarkers and monitor symptoms associated with Parkinson’s disease
- Topline Phase 1b results are expected within six-to-nine weeks, following data unblinding, analysis and interpretation
- The full dataset, including biomarker data, is expected before the end of the year
- Trial is funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK
24 Likes
Here is Siltanen’s preliminary comment as Herantis reports its results on Thursday. 
The webcast starts at 10 AM and can be watched here. The company started a Phase Ib clinical study in Parkinson’s disease with the investigational drug HER-096 in H2 last year. The first results should be ready in the coming weeks, and the full study data will be published by the end of the year. During the review period, the company announced a directed share issue, which was in line with our expectations. Current cash reserves should be sufficient for the completion of Phase Ib and preparation for Phase II, as well as advancing partnership negotiations. For the H1’25 figures, we expect an operating result of -2.1 MEUR and earnings per share of -0.10 euros.
12 Likes
Antti interviewed Herantis Pharma’s CEO Antti Vuolanto after the H1 publications.
Topics:
00:00 Introduction
00:06 Events of the early year
01:09 Phase I study of Parkinson’s disease
02:43 Next steps as results are confirmed
04:10 Preparations for Phase II
05:29 Possible consultation with authorities
06:22 Increase in personnel count
07:20 Highlights from the operating environment
14 Likes
Siltanen has made a new company report after Herantis’ H1 publications.
Herantis’ first half proceeded according to expectations and schedules. The ongoing clinical study is in its final stages, and key results are expected in mid-October. Based on the well-progressed study, we moderately raise our estimate for the success of Phase I. We reiterate our recommendation (add) and raise our target price to 2.1 euros (previously 1.9) based on our cash flow model.
14 Likes
Portfolio Builder: Will Herantis Pharma’s Second Pick Make a Breakthrough?
Herantis Pharma is a high-risk drug development company that develops a drug to slow down Parkinson’s disease. In October, the company expects results from phase 1b patient trials.
13 Likes
Herantis Pharma’s CEO Antti Vuolanto was talking about the company as an investment target at the Stock Investor’s Week.
6 Likes
From KL, there’s a recent article (behind a paywall) titled “Herantis Pharma has all its eggs in one basket - Is there enough money?” and I don’t have credentials, so I don’t know what else the article discusses, but if anyone has credentials and is interested, here’s the link to copy-paste:
1 Like
Based on the CEO’s presentation and interview from yesterday’s stock market week. He said that HP is currently only
3 Likes
You have quoted too short a snippet of text here. The full text says this.
" Among smaller stocks, I want to highlight Denali Therapeutics ahead of its potential first drug approval for Hunter syndrome by Jan. 5. It leverages the company’s technology platform, designed to transport molecules across the blood-brain barrier. While Hunter syndrome represents a relatively small commercial opportunity, Denali has a clinical and preclinical pipeline of assets leveraging this technology, including for Sanfilippo syndrome—where the FDA has granted an accelerated approval path— Fabry disease, Parkinson’s disease, and Alzheimer’s disease, among others. Denali plans to bring one to two candidates to clinical development each year."
So AA is being sought* for the treatment of Sanfilippo syndrome.
Denali’s technology is based on modifying drug substances so that they can cross the blood-brain barrier. This is achieved by attaching the drug substance to a transferrin receptor-binding moiety, which mediates blood-brain barrier penetration via receptor-mediated transcytosis: https://www.denalitherapeutics.com/science/engineering. I find Denali’s technology very interesting because a significant portion of drug candidates targeting the central nervous system fail due to their inability to cross the blood-brain barrier, as recombinant CDNF did previously. In principle, Denali’s technology could make it possible to develop a blood-brain barrier-penetrating version of CDNF, but HER-096 is likely better from the outset because the production of synthetic peptides (like HER-096) is probably cheaper than recombinant proteins. HER-096 crosses the blood-brain barrier as is, so no other modifications are needed for it.
Denali’s Parkinson’s disease drug candidate, on the other hand, is the LRRK2 inhibitor BIIB122, which has been developed in collaboration with Biogen: Pipeline - Denali Therapeutics. Here’s also an earlier news item on the topic in this thread. However, Biogen now seems to be leaving Denali hanging with this compound. A big open question here is whether the patient needs to have an LRRK2 mutation to benefit from this drug?
“This is not the first time Biogen has trimmed around the edges of the Denali collaboration. The biopharma cut work on a Parkinson’s disease clinical trial for BIIB122 (DNL151) just over a year ago as the test, which focused on patients with a certain gene mutation, was not expected to have a readout until 2031. The cut was part of Biogen’s R&D prioritization.
But the companies remain partnered on BIIB122, a selective LRRK2 inhibitor for Parkinson’s disease, a spokesperson confirmed to Fierce Biotech in an email. A 640-patient phase 2b test is being conducted by Biogen for patients with early stage disease.”
Anyway, as TJ noted in the previous video, positive results from other treatments utilizing the same mechanism (i.e., regulation of autophagy / proteostasis) could ultimately also positively affect Herantis’s case. Such results would potentially strengthen the targeting of this signaling pathway as a viable target for Parkinson’s treatment. It is also worth following Anavex news in the near future, because, if I recall correctly, Anavex submitted an application to the EMA for Blarcamesine’s Alzheimer’s disease trials early in the year (Blarcamesine also acts via autophagy regulation) and a decision is expected, I believe, by the end of the year.
* edit: It had not been granted yet. My bad. This is what is being sought next: https://firstwordpharma.com/story/5988246
DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enrollment; planning underway for a global Phase 3 confirmatory study.
8 Likes
I corrected my text above. That AA has not yet been granted, but there is now an open opportunity for it for the treatment of Sanfilippo syndrome. Different medicinal substances are used for the treatment of Sanfilippo syndrome and Parkinson’s disease; Sanfilippo’s drug candidate is DNL126 (N-sulfoglucosamine sulfohydrolase) and Parkinson’s is BIIB122 (LRRK2 inhibitor).
1 Like
Yeah, it’s quite an interesting article. The subordinate clause there is just in a slightly odd place 
1 Like
The price has risen nicely yesterday and today. Soon we can probably expect news?
2 Likes